جستجوی استاد راهنمای دانشگاهی

Zeynep Erson Omayمشاهده پروفایل

استادیار

• Computational Biology
• Genomics
• Epigenomics
• +۶ مورد دیگر

Dr. Zeynep Erson Omay serves as an Assistant Professor in the Department of Neurosurgery and Biomedical Informatics & Data Science at Yale School of Medicine. Her work bridges computational biology with neurosurgical oncology, focusing on precision medicine applications for brain tumors, with particular emphasis on understanding tumor heterogeneity and molecular mechanisms of CNS tumors. Dr. Erson Omay's educational background includes: PhD in Computer Science from Case Western Reserve University (2011) MS in Computer Science from Bilkent University (2005) BS in Computer Science from Bilkent University (2003) Her research focuses on computational analysis of multi-omic datasets to understand tumor heterogeneity, particularly in central nervous system tumors. Dr. Erson Omay specializes in genomic, transcriptomic, and epigenetic profiling of brain tumors, with emphasis on meningiomas, glioblastomas, and rare CNS tumor subtypes. She leads the Erson Lab, which develops bioinformatics approaches to study large datasets and reveal molecular mechanisms in tumor formation, progression, and clinical outlier subgroups. Her work in precision medicine aims to decipher the molecular architecture of individual tumors to guide personalized treatment approaches, with significant contributions to understanding tumor ecosystems and evolutionary patterns in brain cancers. Dr. Erson Omay's scientific contributions span neuro-oncology, computational biology, and precision medicine, with a strong emphasis on translating genomic findings into clinical applications. Her publications demonstrate consistent innovation in applying computational methods to complex neurosurgical problems, with particular focus on tumor heterogeneity, molecular classification, and racial disparities in tumor genomics. Her notable scientific awards include: 10x Genomics 2021 Pilot Award (2022) Mission Bio Tapestri Grant (2022) Case Western Reserve University, Research ShowCASE-Best Poster Award (2007) Dr. Erson Omay actively mentors students and researchers at various levels, including undergraduate students, graduate students, postdocs, and postgraduate associates. She collaborates extensively within Yale's neurosurgery department and across disciplines to advance computational approaches to brain tumor research. Her work is supported by various grants that enable the development of novel bioinformatics platforms for tumor genomic characterization. She leads the Erson Lab, which focuses on three major research areas: Tumor Ecosystem (studying interactions among tumor and immune cells), Tumor Evolution and Heterogeneity (understanding temporal and spatial tumor evolution), and Precision Medicine (applying genomic techniques to personalize brain tumor treatment). The lab employs diverse omics technologies to explore brain tumor biology and develop computational methods for precision medicine applications.

• Neurosurgery
• Neuro-Oncology
• Genomics
• +۴ مورد دیگر

Hasan Alanya is a Researcher in the Department of Neurosurgery at Yale School of Medicine. His work focuses on genomic characterization of brain tumors, including meningiomas, pituitary adenomas, and other neurological disorders. He specializes in molecular pathology, somatic mutations, and the genetic basis of tumor behavior. His research bridges clinical neurosurgery with advanced genomic techniques to understand tumor progression and racial/ethnic variations in disease outcomes. Key research interests include neuro-oncology, somatic mutation analysis, and translational applications of genomic data. His studies investigate how genetic mutations drive tumor development and response to therapy, particularly in pituitary and spinal tumors. Recent work emphasizes the role of thrombocytes in immune responses and the utility of single-cell data for refining bulk genomic analyses. Publications highlight interdisciplinary approaches, combining genomics with clinical observations to address gaps in understanding tumor heterogeneity and treatment strategies. Collaborations span neurosurgery, oncology, and computational biology to advance personalized medicine in neuro-oncology.

• Nuclear Medicine
• Molecular Imaging
• PET Imaging
• +۵ مورد دیگر

Daniel Appelbaum, MD, is a Professor of Radiology at the University of Chicago, specializing in nuclear medicine and molecular imaging. He serves as a radiologist and nuclear medicine physician at the University of Chicago Medicine, where he leads a section involved in multiple oncology PET/CT clinical trials. Dr. Appelbaum chairs the University of Chicago Radioactive Drug Research Advisory Committee (RADRAC) and is an active member of the national Society of Nuclear Medicine Committee on Education. Mallinckrodt Institute of Radiology at Washington University, St. Louis, MO (2000) - Fellowship in Nuclear Medicine University of Chicago, Chicago, IL (1999) - Residency in Diagnostic Radiology Mount Sinai School of Medicine, New York, NY (1995) - MD Cornell University, Ithaca, NY (1991) - BA in English Literature American Board of Radiology Certification (1999) American Board of Nuclear Medicine Certification (2000) Dr. Appelbaum's research focuses on nuclear and molecular imaging in both basic science and clinical settings. His current work includes developing a novel brain imaging agent for multiple sclerosis and a metabolic catalyst to enhance tumor detection with PET imaging. He has pioneered new strategies for computer-aided diagnosis (CAD) in nuclear medicine, for which he holds an AI patent. His research spans oncologic, neurologic, and cardiac applications of PET and PET/CT imaging, with special emphasis on metabolic tumor volume analysis, molecular targeted therapies, and quantitative imaging biomarkers. His laboratory investigates applications of artificial intelligence in radiographic image interpretation, particularly for cancer detection and monitoring treatment response. Analysis of Dr. Appelbaum's recent publications (2015-2025) reveals a strong focus on quantitative nuclear medicine imaging, particularly PET/CT applications in oncology. His work consistently explores metabolic tumor volume as a prognostic marker across various cancers including lung cancer, lymphoma, and neuroendocrine tumors. There is a clear trajectory toward integrating artificial intelligence with nuclear medicine imaging, as evidenced by his research on computer-aided diagnosis systems and quantitative image analysis. His publications span multiple disciplines including oncology, neurology, cardiology, and hematology, demonstrating the broad applicability of nuclear imaging techniques across medical specialties. America's Top Doctor (Castle Connolly, 2014-present) Chicago's Top Doctor (Chicago Magazine, 2012-present) Marc Tetalman Teacher of the Year Award (University of Chicago, 2006-2007) As an educator, Dr. Appelbaum has made significant contributions to nuclear medicine education, serving on the national Society of Nuclear Medicine Committee on Education for many years. He authored the textbook Nuclear Medicine RadCases as a comprehensive review resource for the field. He frequently accepts lecture invitations on nuclear and PET imaging at medical institutions and conferences worldwide. His research program has secured multiple clinical trials funding, particularly in oncology PET/CT applications for monitoring therapy response. Dr. Appelbaum's AI-related patent in computer-aided diagnosis represents a significant translational research achievement with potential clinical impact. Dr. Appelbaum leads a research section at the University of Chicago focused on nuclear and molecular imaging. His team collaborates extensively with oncologists, neurologists, and cardiologists on clinical trials and translational research projects. The group is particularly active in developing novel imaging biomarkers and quantitative analysis methods for cancer imaging. They maintain strong collaborations with computer science researchers for AI development in medical imaging. The section participates in multiple multi-center clinical trials evaluating PET/CT for cancer staging, treatment response assessment, and prognostication across various malignancies.

• Erythropoietic Protoporphyria
• Afamelanotide
• Inborn Errors of Metabolism
• +۷ مورد دیگر

Dr. Janneke Langendonk is a Researcher in the Department of Internal Medicine at Erasmus University Medical Center in Rotterdam, Netherlands. Her work focuses on rare metabolic disorders and their clinical management, with particular expertise in photosensitivity conditions and inborn errors of metabolism. Her primary research interests include: Erythropoietic Protoporphyria and related photosensitivity disorders Inborn Errors of Metabolism Bone health in patients with limited sunlight exposure Hepatic encephalopathy treatments Endocrine disorders including pancreatic neuroendocrine tumors Dr. Langendonk's recent research has examined the impact of minimal sunlight exposure on bone health in erythropoietic protoporphyria patients, investigated treatments for hepatic encephalopathy, and documented the frequencies of various inborn errors of metabolism in adult metabolic centers. Her work often involves cohort studies and systematic reviews to advance understanding of rare conditions that affect small patient populations. She has presented her research on erythropoietic protoporphyria treatment at academic conferences, with her work gaining attention from multiple news outlets and social media platforms including X (formerly Twitter) and Bluesky. Her invited talk in August 2022 on this topic was covered by 4 news outlets and shared by 16 X users. Dr. Langendonk has supervised at least two students or junior researchers and maintains an active research profile with 112 research outputs including articles, book chapters, and review articles. Her collaborative approach is evident in her international co-authorships across multiple publications.

• Neuroendocrine Tumors
• Peptide Receptor Radionuclide Therapy
• Endocrinology
• +۷ مورد دیگر

Hans Hofland is a researcher in the Department of Internal Medicine at Erasmus MC, a leading academic medical center in the Netherlands. His work is centered on endocrinology and oncology, particularly in the field of neuroendocrine tumors and radionuclide therapies. Institution: Erasmus MC School: Faculty of Medicine Department: Department of Internal Medicine Position: Researcher Dr. Hofland’s research focuses on peptide receptor radionuclide therapy (PRRT), neuroendocrine tumors, and endocrine oncology. His work spans clinical trials, treatment guidelines, diagnostic imaging, and biomarker evaluation. He actively contributes to national and international consensus efforts, including those led by the European Neuroendocrine Tumor Society (ENETS). His recent publications highlight expertise in PRRT using agents like [177Lu]Lu-DOTA-TATE and [177Lu]Lu-PSMA-I&T, patient selection, response evaluation, renal protection, and outcomes in diverse populations including elderly patients and those with metastatic disease. The body of work reflects a strong emphasis on real-world evidence, multicentre collaboration, and translational research. Dr. Hofland has contributed to over 130 research outputs, including original articles, reviews, and chapters. His work frequently appears in high-impact journals such as Journal of Neuroendocrinology , European Journal of Nuclear Medicine and Molecular Imaging , and Endocrine-Related Cancer . He has supervised doctoral theses and mentored junior researchers, contributing to academic training in endocrinology and nuclear medicine. While no specific grants are listed, his involvement in large-scale, multi-institutional studies suggests participation in funded research programs. Dr. Hofland is affiliated with a robust clinical and research network in endocrinology, collaborating with experts across Europe. His work supports the advancement of theranostics in oncology and improves clinical management of complex endocrine disorders.

Nancy Duمشاهده پروفایل

دانشیار

• Cancer Research
• Oncology
• Metastasis
• +۵ مورد دیگر

Nancy Du is an Associate Professor of Pathology and Laboratory Medicine at Weill Cornell Medical College specializing in cancer metastasis mechanisms. She holds the Mildred L. and John F. Rasweiler Research Scholar in Cancer Research title and maintains active collaborations with Northwell Health through professional services. B.S., National Tsing Hua University (Taiwan) Ph.D., State University of New York at Stony Brook Her research focuses on: Bcl-xL's non-apoptotic role in metastasis RHAMM isoform B in pancreatic cancer progression Carbon monoxide-based anti-metastatic therapies MicroRNA regulation of tumor suppressors Epigenetic mechanisms in oncogenesis Tumor microenvironment interactions Publications (2024-2019) highlight advancements in: Murine cancer models Epigenetic metastatic drivers Nanotherapy approaches T cell infiltration in tumors miRNA-dysregulated pathways Bcl-xL mutation analysis Scientific honors include: Mildred L. and John F. Rasweiler Research Scholar in Cancer Research Current grants (2024-2027): DoD: Bcl-xL in breast cancer metastasis Manhasset Women's Coalition: CO-based breast cancer prevention NCI: RHAMM B in pancreatic cancer metastasis

• type 1 diabetes
• precision medicine
• machine learning
• +۲ مورد دیگر

Angeliki Makri serves as an Assistant Professor in the Department of Pediatrics within McGill University's Faculty of Medicine and Health Sciences. She holds a Junior Scientist position at the Research Institute of the McGill University Health Centre (IR-MUHC) at the Glen site, where she is affiliated with both the Child Health and Human Development Program and the Center for Evaluative Research in Health (CRES). Dr. Makri's research program focuses on leveraging machine learning approaches to address critical clinical questions in type 1 diabetes. Her work centers on identifying distinct disease subgroups (endotypes) to enable more accurate diagnosis and developing prediction models for diabetes complications that could facilitate targeted prevention strategies. Her research interests span type 1 diabetes, precision medicine, machine learning applications in healthcare, disease heterogeneity, and endotype identification. Analysis of her publication record reveals a strong focus on pediatric endocrinology, genetic disorders, and diabetes research. Her work demonstrates expertise in multiple endocrine neoplasia syndromes, Cushing disease, Wolfram syndrome, and the application of genomic and machine learning approaches to understand disease mechanisms. Recent publications show an increasing emphasis on computational approaches to diabetes research while maintaining her clinical focus on endocrine disorders in children. Dr. Makri collaborates extensively with researchers at the National Institutes of Health, particularly with Dr. Constantine Stratakis and Dr. Maya Lodish, as evidenced by multiple co-authored publications on pediatric endocrine disorders. Her research bridges clinical pediatrics, endocrinology, and computational approaches to advance understanding of complex metabolic diseases in children.

• Endocrine Tumors
• Cancer Genetics
• Targeted Therapy
• +۲ مورد دیگر

Mark Stevenson is a Research Fellow at the University of Oxford, based at the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), where he conducts critical research within the Thakker Group's Academic Endocrine Unit. His work bridges molecular oncology and clinical endocrinology to develop targeted therapies for endocrine-related cancers. Education: BSc (Hons) PhD in cytogenetic analysis of Allium from the University of Birmingham Research Interests: Dr. Stevenson specializes in endocrine tumor genetics, focusing on pancreatic, pituitary, and parathyroid cancers through models of hyperparathyroidism-jaw tumour syndrome and MEN1. His expertise spans molecular oncology—from PRMT5 in ovarian cancer to adenoviral vector development for prostate cancer—and viral oncology via HPV detection in cervical tissue. Current projects prioritize translating genetic insights into diagnostic tools and somatostatin-based therapeutics. Recent Publications: His 2024-2025 output centers on calcium metabolism disorders (e.g., calcilytic therapy for ADH1, cinacalcet for hypercalcemia) and genetic mechanisms in neurodevelopmental/skeletal disorders. Key themes include AP2S1 variants, CRABP2-NFIX interactions, and GNAQ/GNA11 mosaicism, demonstrating a cohesive focus on targeted interventions for endocrine pathologies. Scientific Awards: No specific awards documented in source material Advising and Grants: No current PhD students or grant details are referenced; research appears embedded within the Thakker Group's infrastructure. Research Environment: As a core member of Professor Rajesh Thakker's Academic Endocrine Unit at OCDEM, he leverages Oxford's translational research ecosystem to advance endocrine tumor models and therapeutic validation, with emphasis on clinical applicability.

Spyridoula Marakaمشاهده پروفایل

استادیار

• Endocrinology
• Thyroid Disorders
• Maternal-Fetal Medicine
• +۵ مورد دیگر

Spyridoula Maraka, MD, MS is an Assistant Professor in the Department of Endocrinology and Metabolism at the University of Arkansas for Medical Sciences (UAMS) College of Medicine. She also serves as a Staff Endocrinologist at the Central Arkansas Veterans Healthcare System (CAVHS) and Program Director of the Endocrinology Fellowship. Her research focuses on optimizing thyroid hormone therapy, particularly in pregnancy, and evaluating clinical outcomes of endocrine disorders such as subclinical hypothyroidism and thyroid nodules. Education: Dr. Maraka holds an MD and MS, though specific academic institutions are not detailed in the provided text. Her work emphasizes evidence-based practice, with a focus on systematic reviews and meta-analyses in endocrinology and maternal-fetal medicine. Research Interests: Dr. Maraka’s studies address thyroid dysfunction during pregnancy, levothyroxine overuse, and patient experiences with alternative therapies like desiccated thyroid extract. She investigates practice variations in managing endocrine conditions and explores innovations such as telemedicine delivery via drones. Her work also examines the intersection of endocrine disorders with mental health, including PTSD, and rare diseases like Erdheim-Chester Disease and MEN1 syndrome. Advising & Grants: While no formal advisees are listed, her role as Fellowship Program Director suggests mentorship of trainees. Grants and funding sources are not explicitly mentioned in the provided data. Labs & Teams: Collaborations likely occur through UAMS Endocrinology Division and CAVHS, though specific lab affiliations are not detailed.

Marcello DiStasioمشاهده پروفایل

استادیار

• Neuroimmunology
• Computational Pathology
• Machine Learning in Healthcare
• +۵ مورد دیگر

Marcello DiStasio is an Assistant Professor in the Departments of Pathology and Ophthalmology at Yale School of Medicine . He is also Co-director of the Yale Legacy Tissue Donation Program. His research focuses on neuroimmunology, computational pathology, and integrating spatial omics technologies with traditional histopathology to study diseases of the central nervous system, including neurodegeneration, cancer, and immune dysregulation. Education: MD and PhD from SUNY Health Science Center at Brooklyn, with biomedical engineering training from NYU Polytechnic. Residency and fellowship training at Harvard Medical School-affiliated institutions. Research Interests: DiStasio develops machine learning algorithms to analyze histologic and genomic data, aiming to classify tumors and understand pathologic processes in the brain, retina, spinal cord, and peripheral nervous system. Key areas include spatial omics applications, neuro-oncology, and inflammatory mechanisms in diseases like macular degeneration and inclusion body myositis. Publications: Over 30 peer-reviewed articles focus on spatial biology, single-cell profiling, and computational pathology. Recent work explores tumor microenvironment interactions, immunoprofiling in neuromuscular disorders, and epigenetic states in spermatogenesis. Methodological contributions include tools for aligning spatial omics data with histologic annotations. Labs & Teams: Leads the DiStasio Lab, which bridges computational methods with clinical pathology. Collaborates with the Hafler Lab and Wu Tsai Institute on interdisciplinary projects. Active in the Janeway Society for physician-scientists.

• Neuroendocrine Tumors
• Endocrinology
• Internal Medicine
• +۷ مورد دیگر

W.W. de Herder is a Full Professor in the Department of Internal Medicine at Erasmus MC, a leading academic medical center in the Netherlands. His work is centered within the Faculty of Medicine, where he contributes significantly to clinical and translational research in endocrinology. His research interests focus on neuroendocrine tumors, peptide receptor radionuclide therapy, and endocrine oncology. He has published extensively on conditions such as acromegaly, MEN1 syndrome, and metastatic neuroendocrine tumors, with a strong emphasis on molecular mechanisms, diagnostic approaches, and targeted therapies. The recent trends in his publications highlight a deep engagement with innovative treatments like lutetium-177-based therapy, the role of gut microbiota in carcinoid syndrome, and the epigenetic and clinicopathological features of neuroendocrine metastases. His work bridges clinical practice and advanced research, often involving multidisciplinary collaboration. His scientific achievements have been recognized through several prestigious awards: NVE – Novo Nordisk Award for Endocrinology (2023) ESE Annual Special Recognition Award (2018) Dr. Henry Friesen Award (2017) He has supervised 14 research projects or junior researchers, indicating a strong commitment to mentoring the next generation of scientists and clinicians. Although no specific grants are listed, his extensive publication record and international collaborations suggest sustained funding and research support. His work is highly cited and widely referenced across platforms like Mendeley, Scopus, and academic social media. Dr. de Herder is actively involved in major research networks in endocrinology and oncology, with collaborations spanning multiple countries. His fingerprint analysis reveals dominant activity in neuroendocrine tumors (100%), peptide receptor targeting (36%), and radionuclide therapy (35%), underscoring his leadership in these specialized domains.

Aurel Perrenمشاهده پروفایل

استاد

• Pathology
• Neuroendocrine Tumors
• Pancreatic Cancer
• +۳ مورد دیگر

Prof. Dr. Aurel Perren is Vice Dean for Digitalization at the Faculty of Medicine, University of Bern , and Head of the Institute of Pathology . His research focuses on neuroendocrine tumors, pancreatic cancer, and digital pathology applications. Current academic roles: Vice Dean Digitalization, Faculty of Medicine, University of Bern Institutional affiliation: Institute of Pathology, University of Bern Research Interests : Aurel Perren's work spans pancreatic neuroendocrine neoplasms , thyroid tumor heterogeneity , and AI-driven medical diagnostics . Key areas include metabolic tumor profiling , immune microenvironment dynamics , and digital pathology implementation . Scientific Collaborations & Tools : He contributes to ENETS position statements and develops deep learning-based diagnostic workflows for lymph node metastases and tumor cell fraction quantification. His team investigates 3D tumor mapping via micro-CT radiomics and molecular subtyping of neuroendocrine tumors. Publications & Projects : Recent articles highlight MCT transporter inhibition strategies, molecular subtyping of PanNETs, and validation of NETest liquid biopsy for high-grade neuroendocrine neoplasms. Current projects focus on spatial immune heterogeneity and personalized tumoroid therapies.

• Pathology
• Oncology
• Neuropathology
• +۳ مورد دیگر

Marianne Schmidt Ettrup serves as an Overlæge (Senior Physician) at Aalborg University Hospital within the Department of Pathology, Faculty of Medicine, Aalborg University. Her dual clinical-academic role involves diagnostic pathology and active research, evidenced by 10 publications spanning 2016-2025 including the 4th edition of Denmark's standard pathology textbook Patologi . Her research centers on pathological mechanisms in disease, with emphasis on brain tumors (particularly PDP-type neoplasms linked to multiple endocrine neoplasia), autoimmune disorders (KCNA2 IgG autoimmunity in neuropsychiatry, VEXAS syndrome), and oncological diagnostics . She investigates rare conditions like intradural extramedullary Ewing sarcoma in adolescents, integrating molecular pathology with clinical presentation to address diagnostic challenges in neuro-oncology and immunology. Analysis of her 2022-2025 publications reveals a strong interdisciplinary trajectory bridging pathology with neurology, immunology, and genetics. Her work prioritizes translational research on rare diseases, often through multi-institutional collaborations as seen in the DEMDAS study group. Key contributions include elucidating autoimmune mechanisms in neuropsychiatric disorders and establishing diagnostic criteria for VEXAS syndrome manifestations. No scientific awards were documented in the source material. While specific advisory roles and grant funding details were absent, her extensive co-authorship (e.g., 35+ collaborators on the KCNA2 study) indicates active participation in international research networks. The 2016 DLBCL gene expression dataset contribution further demonstrates engagement with genomic pathology initiatives.

Ty Carrollمشاهده پروفایل

دانشیار

• Endocrinology
• Diabetes
• Thyroid Disorders
• +۳ مورد دیگر

Ty Carroll, MD is an Associate Professor at the Medical College of Wisconsin within the Department of Medicine's Division of Endocrinology and Molecular Medicine. He serves as Director of the Endocrinology, Diabetes, and Metabolism Fellowship Program, overseeing advanced clinical training while maintaining an active adult endocrinology practice focused on complex endocrine disorders. Education: BS in Biochemistry, University of Wisconsin Madison MD, Medical College of Wisconsin Internal Medicine Residency, Medical College of Wisconsin and Affiliated Hospitals Fellowship in Endocrinology, Metabolism, and Clinical Nutrition, Medical College of Wisconsin Dr. Carroll's research centers on refining diagnostic protocols and therapeutic approaches for adrenal disorders, particularly Cushing's syndrome and adrenal insufficiency. His clinical expertise spans diabetes management, thyroid disorders (including cancer), and complex pituitary conditions. He emphasizes patient-centered care with thorough education to tailor treatments to individual needs, as reflected in his leadership of the fellowship program. Analysis of his 12 publications (2016-2025) reveals a consistent focus on adrenal pathophysiology, with 70% addressing Cushing's syndrome diagnostics or management. Key trends include validating novel testing protocols (cosyntropin stimulation, late-night salivary cortisol), establishing assay-specific diagnostic cutoffs, and exploring unconventional presentations like alcohol-induced Cushing syndrome. His work bridges laboratory medicine and clinical practice to improve diagnostic accuracy. As Fellowship Program Director, Dr. Carroll mentors future endocrinologists through structured clinical training. While specific grant details aren't public, his high-impact publications in journals like Journal of the Endocrine Society and World Journal of Surgery indicate active research funding in adrenal diagnostics and therapeutic optimization.

Erica Blouchمشاهده پروفایل

استادیار مدعو

• Cancer Genetic Counseling
• Hereditary Endocrine Tumor Syndromes
• Breast Cancer Genetics
• +۳ مورد دیگر

Erica Blouch, MS, CGC is an Adjunct Assistant Professor in the Genetic Counseling program at the MGH Institute of Health Professions (IHP) and serves as a Senior Genetic Counselor at the Mass General Cancer Center. She has worked at the MGH Center for Cancer Risk Assessment since 2010, seeing patients in various cancer predisposition clinics including the Breast/Ovarian and GI Cancer Genetics clinic. Her educational background includes a BS in Molecular Biology from Lehigh University and an MS in Genetic Counseling from Brandeis University. Blouch specializes in hereditary endocrine tumor syndromes including Cowden syndrome, MEN1, MEN2, and pheochromocytoma syndromes, and serves as the lead genetic counselor of the MGH Endocrine Tumor Genetics clinics. Her research focuses on the challenges in genetic counseling for hereditary cancer syndromes, factors affecting genetic counseling referral and completion, and optimal resource utilization in genetic counseling services. She has witnessed significant advancements in the field, from single-gene testing to panel testing of up to 80 genes at a time, and has contributed to increased public awareness following Angelina Jolie's BRCA1 disclosure in 2013/2014. As an educator, Blouch teaches the comprehensive 14-week Cancer Genetic Counseling course at IHP, where students complete standardized patient scenarios focused on breast cancer counseling and participate in clinical rotations in cancer clinics. Her work bridges clinical practice and education, emphasizing the importance of understanding hereditary causes of cancer to advance cancer biology knowledge and improve patient care.